Currently, the post remission treatment of patients affected by acute myeloid leukemias is based on the genetic profile of leukemic cells at diagnosis and on the level of minimal residual disease after induction and consolidation chemotherapy mainly detected by multiparameter flow cytometry and by q-PCR for the assessment of fusion transcripts levels (i.e., CBFB-MYH11 and RUNX1-RUNX1T1 and PML-RARα) of mutations, mainly NPM1 [35,36]. Here, NPM1 is linked to acute myeloid leukemia.